Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial - Concepedia

Concepedia

Publication | Open Access

Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial

DOI Full Paper Access

44

Citations

16

References

2022

Year

María Eugenia Toledo-Romaní, Mayra García-Carmenate, Carmen Valenzuela‐Silva, Waldemar Baldoquín Rodríguez, Marisel Martínez-Pérez, Meiby Rodríguez-González, Beatriz Paredes-Moreno, Ivis Mendoza-Hernández, Raúl González-Mujica Romero, Oscar Samón-Tabío,

The Lancet Regional Health - Americas

Abstract

This study received funds from the National Fund for Science and Technology (FONCI-CITMA-Cuba, contract 2020-20) of the Ministry of Science, Technology and Environment of Cuba.

References

	Year	Citations

Page 1